Differential effects of FTY720 on the B cell compartment in a mouse model of multiple sclerosis

Abstract

BackgroundMP4-induced experimental autoimmune encephalomyelitis (EAE) is a mouse model of multiple sclerosis (MS), which enables targeted research on B cells, currently much discussed protagonists in MS pathogenesis. Here, we used this model to study the impact of the S1P1 receptor modulator FTY720 (fingolimod) on the autoreactive B cell and antibody response both in the periphery and the central nervous system (CNS).MethodsMP4-immunized mice were treated orally with FTY720 for 30 days at the peak of disease or 50 days after EAE onset. The subsequent disease course was monitored and the MP4-specific B cell/antibody response was measured by ELISPOT and ELISA. RNA sequencing was performed to determine any effects on B cell-relevant gene expression. S1P1 receptor expression by peripheral T and B cells, B cell subset distribution in the spleen and B cell infiltration into the CNS were studied by flow cytometry. The formation of B cell aggregates and of tertiary lymphoid organs (TLOs) was evaluated by histology and immunohistochemistry. Potential direct effects of FTY720 on B cell aggregation were studied in vitro.ResultsFTY720 significantly attenuated clinical EAE when treatment was initiated at the peak of EAE. While there was a significant reduction in the number of T cells in the blood after FTY720 treatment, B cells were only slightly diminished. Yet, there was evidence for the modulation of B cell receptor-mediated signaling upon FTY720 treatment. In addition, we detected a significant increase in the percentage of B220+ B cells in the spleen both in acute and chronic EAE. Whereas acute treatment completely abrogated B cell aggregate formation in the CNS, the numbers of infiltrating B cells and plasma cells were comparable between vehicle- and FTY720-treated mice. In addition, there was no effect on already developed aggregates in chronic EAE. In vitro B cell aggregation assays suggested the absence of a direct effect of FTY720 on B cell aggregation. However, FTY720 impacted the evolution of B cell aggregates into TLOs.ConclusionsThe data suggest differential effects of FTY720 on the B cell compartment in MP4-induced EAE.Electronic supplementary materialThe online version of this article (doi:10.1186/s12974-017-0924-4) contains supplementary material, which is available to authorized users.

Anti-CD52 antibody treatment depletes B cell aggregates in the central nervous system in a mouse model of multiple sclerosis

“…The resulting complete or partial disappearance of OCBs in the CSF of a group of RRMS patients treated with natalizumab [ 41 , 42 ] indicates that constant supply from the periphery is necessary to maintain B cell aggregates if they are considered at least partially responsible for OCB development. We have previously shown that treatment with the S1P 1 receptor agonist fingolimod, which inhibits lymphocyte egress from secondary lymphoid organs, prevented the development of B cell aggregates in the CNS in acute MP4-induced EAE, while it did not affect existing infiltrates in the chronic stage of the disease [ 43 ]. This rather suggests the independence of B cell aggregates, at least partially, from peripheral support.…”

Impact of Glatiramer Acetate on B Cell-Mediated Pathogenesis of Multiple Sclerosis

“…As a consequence of the results of studies of B cell-depleting therapies, the mechanism of action of more established DMTs thought to target T cells has been re-evaluated in light of the emerging importance of B cells in the pathogenesis of MS [ 14 , 15 , 17 ]. Indeed, a number of DMTs, including alemtuzumab [ 50 ], daclizumab [ 51 ], fingolimod [ 52 , 53 ], dimethyl fumarate [ 54 ], cladribine [ 55 ], and GA (see Sect. 4 ), have now been shown to exert an effect on B cells.…”

Different Point of View to the Autoimmune Diseases and Treatment with Acupuncture

“…Multiple sclerosis (MS) is a demyelinating and neurodegenerative autoimmune disease of the central nervous system [ 10 ]. Although the etiology is not clear, but genetic, environmental and infectious agents are thought to be effective in the onset and development of the disease [ 11 ].…”